Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cidara Thera (CDTX)

Cidara Thera (CDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cidara Thera 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 USA

www.cidara.com Employees: 38 P: 858-752-6170

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.

Key Statistics

Overview:

Market Capitalization, $K 6,948,960
Enterprise Value, $K 6,752,780
Shares Outstanding, K 31,439
Float, K 30,216
% Float 96.11%
Short Interest, K 1,882
Short Float 0.00%
Days to Cover 2.23
Short Volume Ratio 0.32
% of Insider Shareholders 3.89%
% of Institutional Shareholders 35.82%

Financials:

Annual Sales, $ 1,280 K
Annual Net Income, $ -169,830 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -83,230 K
EBIT, $ -194,880 K
EBITDA, $ -194,460 K

Growth:

1-Year Return 725.74%
3-Year Return 738.56%
5-Year Return 371.02%
5-Year Revenue Growth -93.88%
5-Year Earnings Growth 4.89%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.43 on 11/06/25
Next Earnings Date 03/05/26
Earnings Per Share ttm -10.12
EPS Growth vs. Prev Qtr 13.33%
EPS Growth vs. Prev Year 39.92%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 04/24/24

CDTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -45.52%
Return-on-Assets % -38.31%
Profit Margin % -13,267.97%
Debt/Equity 0.00
Price/Sales -927.77
Price/Cash Flow N/A
Price/Book 13.29
Book Value/Share 16.66
Interest Coverage -7.26
60-Month Beta 1.52
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar